Key Highlights
- Neurosterix initiates with a $63 million Series A financing, aiming to transform the treatment landscape for neurological disorders.
- The company acquires Addex’s leading allosteric modulator technology, set to expedite the discovery of targeted, efficacious drugs.
- Neurosterix’s lead program focuses on schizophrenia treatment, with a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator (M4 PAM).
Source: Business Wire
Notable Quotes
- “We are excited to launch Neurosterix with the support of our founding investors, Perceptive Advisors and Acorn Bioventures, to rapidly advance our pipeline of potentially best-in-class therapies targeting patients who suffer from debilitating neurological disorders. Our goal at Neurosterix is to develop new medicines based on allosteric modulation that overcome the burdens of traditional drugs and provide patients with the potential to dramatically improve their lives.” – Tim Dyer, CEO at Neurosterix
- “We recognize the potential of not only the assets now being developed within Neurosterix, but also the potential of the platform to develop a broad-based set of life-changing medicines.” – Fred Callori, Managing Director, Venture at Perceptive Advisors
SoHC's Take
Neurosterix’s launch represents a significant step forward in the field of neurology. By focusing on allosteric modulators, the company aims to bring a new level of precision and efficacy to the treatment of neurological disorders. This approach could offer hope to millions of patients worldwide, suffering from conditions that are currently difficult to manage. With strong backing from influential venture funds and the acquisition of a pioneering technology platform, Neurosterix is well-positioned to make a lasting impact on the treatment of neurological disorders. The industry will be watching closely as Neurosterix progresses its promising pipeline towards clinical trials and beyond, potentially setting a new standard for therapeutic interventions in neurology.
